Penpulimab (Anti-Pd-1) Combined With Anlotinib As First-Line Therapy For Unresectable Hepatocellular Carcinoma (Uhcc): Updated Results From A Phase Ib/Ii Study.
JOURNAL OF CLINICAL ONCOLOGY(2021)
Abstract
306Background: Combined therapy of an immune checkpoint inhibitor with a targeted antiangiogenic agent had been proved to be effective for the treatment of uHCC. Penpulimab was engineered to elimin...
MoreTranslated text
Key words
hepatocellular carcinoma,unresectable hepatocellular carcinoma,anlotinib,first-line
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined